Table 2. Connectivity map analysis of TNBC subtypes.
| Rank | Drug | Dose | Score |
|---|---|---|---|
| Basal-like 1 TNBCs versus rest of TNBCs | |||
| 1 | N-acetylmuramic acid | 14 μM | 1 |
| 2 | Paclitaxel | 5 μM | 0.947 |
| 5 | Metformin | 24 μM | 0.916 |
| 6099 | Oxantel | 7 μM | −0.95 |
| 6100 | Azathioprine | 14 μM | −1 |
| Basal-like 2 TNBCs versus rest of TNBCs | |||
| 1 | N-acetylmuramic acid | 14 μM | 1 |
| 2 | Paclitaxel | 5 μM | 0.947 |
| 5 | Metformin | 24 μM | 0.916 |
| 6099 | Oxantel | 7 μM | −0.95 |
| 6100 | Azathioprine | 14 μM | −1 |
| Immunomodulatory TNBCs versus rest of TNBCs | |||
| 1 | Chlorpromazine | 11 μM | 1 |
| 3 | Metformin | 24 μM | 0.968 |
| 6099 | Morantel | 11 μM | −0.993 |
| 6100 | Trichostatin A | 100 nM | −1 |
| Luminal Androgen Receptor TNBCs versus rest of TNBCs | |||
| 1 | Trichostatin A | 1 μM | 1 |
| 2 | Fulvestrant | 1 μM | 0.957 |
| 6096 | Poiglitazone | 10 μM | −0.949 |
| 6089 | Rosiglitazone | 10 μM | −0.901 |
| 6100 | AR-A014418 | 10 μM | −1 |
| Mesenchymal stem like TNBCs versus rest of TNBCs | |||
| 1 | Sirolimus | 100 nM | 1 |
| 2 | Colforsin | 50 μM | 0.95 |
| 4 | Resveratrol | 50 μM | 0.949 |
| 5 | Fulvestrant | 1 μM | 0.943 |
| 6096 | Rosiglitazone | 10 μM | −0.95 |
| 6097 | Tretinoin | 1 μM | −0.962 |
| Mesenchymal TNBCs versus rest of TNBCs | |||
| 1 | Allantoin | 25 μM | 1 |
| 2 | Chrysin | 16 μM | 0.971 |
| 6086 | Tretinoin | 1 μM | −0.841 |
| 6099 | Paroxetine | 1 μM | −0.934 |
| 6100 | Verteporfin | 3 μM | −1 |